Potential interaction of troglitazone and cyclosporine

Bruce Kaplan, Gary Friedman, Martin Jacobs, Ronald Viscuso, Neil Lyman, Penny DeFranco, Luigi Bonomini, Shamkant P. Mulgaonkar

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug Administration for use in type II diabetes mellitus. Although troglitazone is not metabolized by the cytochrome p450 3A isozyme family, it is a potential inducer of this system. Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations. Methods. We report a case of a stable renal transplant patient who had a decrease in CsA concentration after beginning troglitazone and who subsequently developed an acute rejection episode. We then reviewed all stable renal patients begun on troglitazone over the previous 6 months. Results. The seven transplant patients who had been started on troglitazone therapy experienced a statistically and clinically significant decrease in CsA 12-hr trough levels immediately after the institution of troglitazone therapy. Conclusions. A potential interaction exists between troglitazone and CsA. Transplant patients on CsA who receive troglitazone therapy should be monitored closely.

Original languageEnglish (US)
Pages (from-to)1399-1400
Number of pages2
JournalTransplantation
Volume65
Issue number10
DOIs
StatePublished - May 27 1998
Externally publishedYes

Fingerprint

troglitazone
Cyclosporine
Transplants
Kidney
Cytochrome P-450 CYP3A
Rifampin
Phenobarbital

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Kaplan, B., Friedman, G., Jacobs, M., Viscuso, R., Lyman, N., DeFranco, P., ... Mulgaonkar, S. P. (1998). Potential interaction of troglitazone and cyclosporine. Transplantation, 65(10), 1399-1400. https://doi.org/10.1097/00007890-199805270-00021

Potential interaction of troglitazone and cyclosporine. / Kaplan, Bruce; Friedman, Gary; Jacobs, Martin; Viscuso, Ronald; Lyman, Neil; DeFranco, Penny; Bonomini, Luigi; Mulgaonkar, Shamkant P.

In: Transplantation, Vol. 65, No. 10, 27.05.1998, p. 1399-1400.

Research output: Contribution to journalArticle

Kaplan, B, Friedman, G, Jacobs, M, Viscuso, R, Lyman, N, DeFranco, P, Bonomini, L & Mulgaonkar, SP 1998, 'Potential interaction of troglitazone and cyclosporine', Transplantation, vol. 65, no. 10, pp. 1399-1400. https://doi.org/10.1097/00007890-199805270-00021
Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P et al. Potential interaction of troglitazone and cyclosporine. Transplantation. 1998 May 27;65(10):1399-1400. https://doi.org/10.1097/00007890-199805270-00021
Kaplan, Bruce ; Friedman, Gary ; Jacobs, Martin ; Viscuso, Ronald ; Lyman, Neil ; DeFranco, Penny ; Bonomini, Luigi ; Mulgaonkar, Shamkant P. / Potential interaction of troglitazone and cyclosporine. In: Transplantation. 1998 ; Vol. 65, No. 10. pp. 1399-1400.
@article{ba044e22bbcb453bbaad2deb02429e0a,
title = "Potential interaction of troglitazone and cyclosporine",
abstract = "Background: Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug Administration for use in type II diabetes mellitus. Although troglitazone is not metabolized by the cytochrome p450 3A isozyme family, it is a potential inducer of this system. Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations. Methods. We report a case of a stable renal transplant patient who had a decrease in CsA concentration after beginning troglitazone and who subsequently developed an acute rejection episode. We then reviewed all stable renal patients begun on troglitazone over the previous 6 months. Results. The seven transplant patients who had been started on troglitazone therapy experienced a statistically and clinically significant decrease in CsA 12-hr trough levels immediately after the institution of troglitazone therapy. Conclusions. A potential interaction exists between troglitazone and CsA. Transplant patients on CsA who receive troglitazone therapy should be monitored closely.",
author = "Bruce Kaplan and Gary Friedman and Martin Jacobs and Ronald Viscuso and Neil Lyman and Penny DeFranco and Luigi Bonomini and Mulgaonkar, {Shamkant P.}",
year = "1998",
month = "5",
day = "27",
doi = "10.1097/00007890-199805270-00021",
language = "English (US)",
volume = "65",
pages = "1399--1400",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Potential interaction of troglitazone and cyclosporine

AU - Kaplan, Bruce

AU - Friedman, Gary

AU - Jacobs, Martin

AU - Viscuso, Ronald

AU - Lyman, Neil

AU - DeFranco, Penny

AU - Bonomini, Luigi

AU - Mulgaonkar, Shamkant P.

PY - 1998/5/27

Y1 - 1998/5/27

N2 - Background: Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug Administration for use in type II diabetes mellitus. Although troglitazone is not metabolized by the cytochrome p450 3A isozyme family, it is a potential inducer of this system. Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations. Methods. We report a case of a stable renal transplant patient who had a decrease in CsA concentration after beginning troglitazone and who subsequently developed an acute rejection episode. We then reviewed all stable renal patients begun on troglitazone over the previous 6 months. Results. The seven transplant patients who had been started on troglitazone therapy experienced a statistically and clinically significant decrease in CsA 12-hr trough levels immediately after the institution of troglitazone therapy. Conclusions. A potential interaction exists between troglitazone and CsA. Transplant patients on CsA who receive troglitazone therapy should be monitored closely.

AB - Background: Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug Administration for use in type II diabetes mellitus. Although troglitazone is not metabolized by the cytochrome p450 3A isozyme family, it is a potential inducer of this system. Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations. Methods. We report a case of a stable renal transplant patient who had a decrease in CsA concentration after beginning troglitazone and who subsequently developed an acute rejection episode. We then reviewed all stable renal patients begun on troglitazone over the previous 6 months. Results. The seven transplant patients who had been started on troglitazone therapy experienced a statistically and clinically significant decrease in CsA 12-hr trough levels immediately after the institution of troglitazone therapy. Conclusions. A potential interaction exists between troglitazone and CsA. Transplant patients on CsA who receive troglitazone therapy should be monitored closely.

UR - http://www.scopus.com/inward/record.url?scp=0032571982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032571982&partnerID=8YFLogxK

U2 - 10.1097/00007890-199805270-00021

DO - 10.1097/00007890-199805270-00021

M3 - Article

C2 - 9625027

AN - SCOPUS:0032571982

VL - 65

SP - 1399

EP - 1400

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -